Arizona Rep. Gosar reintroduces bill ending LEGAL IMMUNITY for vaccine makers

 HR 4668 Introduction

- Rep. Paul Gosar (R-AZ) reintroduced HR 4668 to repeal protections for vaccine manufacturers from lawsuits.

- The goal is to allow individuals harmed by vaccines to sue in state or federal court.

## Background on Vaccine Liability

- Vaccine manufacturers have been largely immune from lawsuits since the National Childhood Vaccine Injury Act (NCVIA) in 1986.

- Individuals must seek compensation through the federal Vaccine Injury Compensation Program (VICP), which is criticized for being slow and inefficient.

## Context of the Bill

- The bill emerges amid growing concerns over vaccine safety, especially regarding COVID-19 vaccines.

- Aims to bypass the Countermeasures Injury Compensation Program (CICP), which approved only 39 of nearly 14,000 COVID-related claims.

## Arguments for and Against the Bill

- Proponents:

- Ending immunity would make manufacturers accountable.

- Could improve transparency regarding vaccines.

- Opponents:

- Warn that it might disrupt the vaccine supply.

- Citing past fears from the 1980s that litigation could drive companies out of production.

## Support and Current Status

- The bill has 28 cosponsors and bipartisan recognition of flaws in compensation systems.

- Its future remains uncertain.

## Additional Context

- Gosar, a former dentist, has previously introduced similar legislation, HR 9828, which also aimed to amend federal law to allow lawsuits against vaccine makers.

## Criticism of Current Systems

- VICP has paid about $5 billion across 25,000 claims, but critics argue the process is unfair and imposes high burdens on claimants.

## Potential Changes

- The bill could remove critical protections from NCVIA and the PREP Act of 2005.

- It would allow for retroactive claims dating back to the VICP's launch in 1988.

## Recent Discussions

- A Senate hearing highlighted the need for reform in vaccine liability, with some pro-vaccine lawmakers agreeing.

- Advocates describe NCVIA as a major error that eliminated accountability for manufacturers, while critics express concern over the stability of vaccine supply.

- Gosar and his supporters argue that litigation would encourage better transparency and safety among vaccine manufacturers.

https://www.naturalnews.com/2025-07-28-gosar-reintroduces-bill-ending-immunity-vaccine-makers.html